British American Tobacco (BAT)'s "modern oral" portfolio has been one of the main drivers helping the company achieve good results in 2019 for its next-generation products category, which overall increased globally by 36.9%
Submit your access request to explore how it streamlines access to critical market and regulatory insights
"*" indicates required fields